<rp id="yivzh"></rp>

      1. <th id="yivzh"></th>
          廣東威爾醫院,wellclinic,威爾醫院骨科
          醫院公益
          特邀專家

          門診時間(無假日醫院)
          早上8:00 - 晚上21:00

          緊急聯系電話:020-38063333

           

          夏洪平

          新加坡國立癌癥中心項目負責人
          維也納醫科大學癌癥中心項目負責人

          個人簡介
          夏洪平, 男, 醫師/博士/教授,博士生導師, 國家“千人計劃”青年項目和“江蘇省特聘教授” 獲得者。 1982 年出生于安徽省, 2011 年畢業于香港大學獲博士學位, 曾在維也納醫科大學癌癥中心和新加坡國立癌癥中心從事惡性腫瘤的轉化醫學與精準治療研究,已作為項目負責人( Principle Investigator, PI)主持國家自然科學基金,National Medical Research Council ( NMRC,新加坡國家醫學研究委員會)基金和Singhealth Foundation(新加坡保健服務集團基金)課題多項,在 Hepatology (IF: 12.08),ACS Nano (IF: 13.33), Gut (IF: 14.92), Journal of Hepatology (IF: 11.34), Nanoscale (IF:7.8), Neuro-Oncology (IF: 7.4) 和 The Journal of Biological Chemistry (IF: 5.12) 等國際期刊雜志上發表相關論著三十余篇 (其中第一作者/通訊作者論文 28 篇),影響因子( IF)>10的 5 篇, IF>5 的 16 篇,論文引用>1500 次, 申請專利多項。于 2016 年入選國家“千人計劃”青年項目和“江蘇省特聘教授”,加盟南京醫科大學基礎醫學院病理學系和南京醫科大學附屬逸夫醫院臨床病理與檢驗中心組建課題組,研究方向將主要集中在惡性腫瘤分子病理,分子影像與代謝,早期診斷和個性化靶向精準治療及納米介導的分子生物靶向藥物研發。 目前擔任國家自然科學基金通訊評審專家和 World Journal ofGastroenterology (IF: 2.547), Hepatoma Research 等雜志的 Editorial Board Member,也是多個雜志如 Annals of Oncology (IF: 7.384), Oncotarget (IF: 6.6), Hepatology (IF:12.08) 和Nano Letters (IF: 13.6)等的特約審稿人。

          學術兼職:
          美國癌癥協會會員;
          環太平洋大學聯盟博士生協會執行委員會委員;
          美國華人醫藥科學家協會會員;
          維也納醫科大學青年科學家協會會員;
          新加坡國立癌癥中心青年科學家協會會員;
          新加坡中國學生學者聯合會會員;

          近年部分代表性論文著作:
          (1) Xia H, Chen J, Shi M, Gao H, Sekar K, Seshachalam VP, Ooi LL, Hui KM. EDIL3 isa novel regulator of epithelial mesenchymal transition controlling early recurrence ofhepatocellular carcinoma. J Hepatol. 2015 Oct; 63(4):863-73. (IF:11.34)
          (2) Ling D*, Xia H*, et al. pH-Sensitive Nanoformulated Triptolide as a TargetedTherapeutic Strategy for Hepatocellular Carcinoma. ACS Nano. 2014 Aug26;8(8):8027-39. (*Co-first author). (IF: 13.33).
          (3) Xia H, et al. MiR-216a/217-induced epithelial-mesenchymal transition targets PTENand SMAD7 to promote drug resistance and recurrence of liver cancer. Hepatology.2013 Aug; 58(2):629-41. (IF: 12.08).
          (4) Xia H, et al. pH-Sensitive Pt Nanocluster Assembly Overcomes Cisplatin Resistanceand Heterogeneous Stemness of Hepatocellular Carcinoma. ACS Cent. Sci., 2016, 2(11), pp 802–811.
          (5) Xia H, et al. MELK is an oncogenic kinase essential for early hepatocellular
          carcinoma recurrence. Cancer Lett. 2016 Dec 1;383(1):85-93. (IF: 5.99)2
          (6) Chen J, Xia H, et al. ECT2 regulates the Rho/ERK signalling axis to promote earlyrecurrence in human hepatocellular carcinoma. J Hepatol. 2015 Jun;62(6):1287-95.(IF: 11.34).
          (7) Chen J, Muthukumar Rajasekaran, Xia H,….The microtubule-associated proteinPRC1 promotes early recurrence of hepatocellular carcinoma in association with theWnt/β-catenin signalling pathway. Gut. 2016 Sep;65(9):1522-34. (IF: 14.92).
          (8) Han J*, Xia H*, Wu Y, Kong SN, Deivasigamani A, Xu R, Hui KM, Kang Y.Single-layer MoS2 nanosheet grafted upconversion nanoparticles for near-infraredfluorescence imaging-guided deep tissue cancer phototherapy. Nanoscale. 2016 Apr14;8(15):7861-5. (*Co-first author). (IF: 7.8).
          (9) Li S, …, Xia H#. Protein tyrosine phosphatase PTPN3 promotes drug resistance andstem cell-like characteristics in ovarian cancer. Sci Rep. 2016 Nov 11;6:36873. doi:10.1038/srep36873. (#Corresponding author) (IF:5.23).
          (10) Jiang X, … , Xia H#. HSP47 promotes glioblastoma stem-like cell survival bymodulating tumor microenvironment extracellular matrix through TGF-β pathway.ACS Chem Neurosci. 2016. PMID:27696866 (#Corresponding author) (IF:4.34).
          (11) Miao L, … , Xia H#, Wang Y. Loss of long noncoding RNA FOXF1-AS1 regulatesepithelial-mesenchymal transition, stemness and metastasis of non-small cell lungcancer cells. Oncotarget. 2016 Aug 26. doi: 10.18632/oncotarget.11630(#Corresponding author) (IF:5.01).
          (12) Jiang X, … , Xia H #. Increased level of H19 long noncoding RNA promotesinvasion, angiogenesis, and stemness of glioblastoma cells. J Neurosurg. 2015 Aug14:1-8. (#Corresponding author) (IF:3.74)
          (13) Xia, H, et al. The Over-Expression of Survivin Enhances the ChemotherapeuticEfficacy of YM155 in Human Hepatocellular Carcinoma. Oncotarget. 2015 Mar 20;6(8):5990-6000. (IF: 5.01).
          (14) Shen L, …, Xia H#, Zhuang Z. Long noncoding RNA MALAT1 promotes brainmetastasis by inducing epithelial-mesenchymal transition in lung cancer. JNeurooncol. 2015; 121 (1):101-8. (#Corresponding author) (IF: 3.1).
          (15) Hu M, … , Xia H#. Loss of miR-1258 contributes to carcinogenesis and progressionof liver cancer through targeting CDC28 protein kinase regulatory subunit 1B.Oncotarget. 2016 Jul 12;7(28):43419-43431. (#Corresponding author) (IF: 5.01).
          (16) Xia H, … , Jiang X. MiR-218 sensitizes glioma cells to apoptosis and inhibitstumorigenicity by regulating ECOP-mediated suppression of NF-κB activity.Neuro-oncology, 2013. 15(4): p. 413-422. (IF: 6.18)
          (17) Wang Y*, Xia H*, et al. Axl-altered microRNAs regulate tumorigenicity andgefitinib resistance in lung cancer. Cell Death Dis. Cell Death Dis. 2014 May15;5:e1227. (*Co-first author). (IF: 6.044)
          (18) Xia H, et al. Mechanism of cancer drug resistance and the involvement ofnoncoding RNAs. Curr Med Chem. 2014; 21(26):3029-41. (IF: 4.07)
          (19) Xia H, et al. Loss of brain-enriched miR-124 enhances the stem-like traits andinvasiveness of glioma cells. J Biol Chem. 2012 Mar 23;287(13):9962-71. (IF: 5.12)
          (20) Xia H, et al. miR-200a regulates epithelial-mesenchymal to stem-like transition viaZEB2 and beta-catenin signaling. J Biol Chem. 2010 Nov 19;285(47):36995-7004.(IF: 5.12)

           

           
          分享到:
          • 國家衛生部
          • 國家食藥監局
          • 中國醫師協會
          • 中華醫學會
          • 上海衛生局
          • 世界衛生組織